The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Merck’s oncology drug Keytruda will outpace all Rx brands by global sales in 2028, as Roche rides its biologics stable to become the frontrunner among pharma companies, according to a five-year World ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

Jan 12 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of Merck & Co's (MRK.N), opens new tab blockbuster immunotherapy Keytruda in combination with ...

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...

Merck & Co. raised its sales forecast amid increased demand for Keytruda, its blockbuster cancer treatment that now accounts for 40% of revenue, and a surprisingly strong result from its controversial ...